Aspen Neuroscience has received adoption of Sasineprocel as the official nonproprietary name for its investigational autologous cell therapy previously known as ANPD001, the company announced. The designation was approved by the World Health Organization’s International Nonproprietary Names Expert Group and cleared by the American Medical Association’s United States Adopted Names Council, with publication pending, according to the company.
Sasineprocel is an autologous dopaminergic neuron precursor cell therapy derived from a patient’s own induced pluripotent stem cells generated from a skin biopsy. It is designed to replace dopamine‑producing neurons lost in Parkinson’s disease without the need for immunosuppressive drugs. The therapy is administered via image‑guided intracranial injection to the putamen, the brain region involved in movement control.
The therapy is being evaluated in Aspen’s Phase 1/2a ASPIRO clinical study for individuals with moderate to advanced Parkinson’s disease. According to the company, the ASPIRO trial continues to assess safety and potential efficacy, and Sasineprocel has previously received Fast Track designation from the U.S. Food and Drug Administration.
Aspen Neuroscience is a clinical‑stage biotechnology company focused on developing personalized regenerative therapies for neurodegenerative and other serious diseases. The nonproprietary naming milestone reflects regulatory and clinical progress for Sasineprocel as Aspen advances toward later‑stage development and potential future commercialization.
